Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector

International Journal of Cancer

Volumn 71, Issue 3, 1997, Pages 377-382

  Asgari, Kekule ^a,b   Sesterhenn, Isabell A ^c   McLeod, David G ^a,b   Cowan, Kenneth ^d   Moul, Judd W ^a,b   Seth, Prem ^d   Srivastava, Shiv ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; EXPRESSION VECTOR; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SUBCUTANEOUS NODULE; TUMOR SUPPRESSOR GENE; VIRUS EXPRESSION;

ADENOVIRIDAE; ANIMALS; CELL DIVISION; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECOMBINANT PROTEINS; TIME FACTORS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030943955     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970502)71:3<377::AID-IJC13>3.0.CO;2-D     Document Type: Article

References (28)

1. APRIKIAN, A.G., SARKIS, A.S., FAIR, W.R., ZHANG, Z.F., FUKAS, Z. and CORDON-CARDO, C., Immunohistochemical determination of p53 protein nuclear accumulation in prostate adenocarcinoma. J. Urol., 151, 276-1280 (1994).
2. BAUER, J.J., SESTERHENN, I.A., MOSTOFI, K.P., MCLEOD, D.G., SRIVASTAVA, S. and MOUL., J.W., p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy. Clin. Cancer Res., 1, 1295-1300 (1995).
3. BAUER, J.J., SESTERHENN, I.A., MOSTOFI, K.F., MCLEOD, D.G., SRIVASTAVA, S. and MOUL, J.W., Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer patients. J. Urol., 156, 1511-1516 (1996).
4. BOOKSTEIN, R., MACGROGAN, D., HISENBECK, S.G., SHARKEY, F. and ALLRED, D.C., p53 mutated in a subset of advanced stage prostate cancers. Cancer Res., 53, 3369-3373 (1993).
5. BRODY, S.L., JALLE, H.A., HAN, S.K., WERSTO, R.P. and CRYSTAL, R.G., Direct in vivo gene transfer and expression in malignant cells using adenovirus vectors. Hum. Gene Therapy, 5, 437-447 (1994).
6. DAMERON, K.M., VOLPERT, O.V., TAINSKY, M.A. and BOUCK, N., Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582-1584 (1994).
7. DISJENS, W.N., VAN DER WEIDEN, M.M., SCHROEDER, F.H., BOSMAN, F.T. and TRAPMAN, J., Frequency and characterization of p53 mutations in primary metastatic human prostate cancer. Int. J. Cancer, 56, 630-633 (1994).
8. EASTHAM, J.A., HALL, S.J., SEHGAL, I., WANG, J., TIMME, T.L., YANG, G., CONNELL-CROWLEY, L., ELLEDGE, S.J., ZHANG, W.W. and HARPER, J.W., In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55, 5151-5155 (1995).
9. GREENBLATT, M.S., BENNET, W.P., HOLLSTEIN, M. and HARRIS, C.C., Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-1878 (1994).
10. HARTWELL, L.H. and KASTAN M.D., Cell cycle control and cancer. Science. 266, 1821-1828 (1994).
11. HEIDENBERG, H.B., BAUER, J.J., MCLEOD, D.G., MOUL, J.W. and SRIVASTAVA, S., The role of p53 tumor suppressor gene in prostate cancer, a possible biomarker? Urology (1996). (In press).
12. HEIDENBERG, H.B., SESTERHENN, I.A., GADDIPATI, J.P., WEGHORST, C.M., BUZZARD, G.S., MOUL, J.W. and SRIVASTAVA, S., Alteration tumor suppressor gene p53 in high fraction of hormone refractory prostate cancer. J. Urol., 154, 414-421 (1995).
13. ISSACS, W.B., CARTER, B.S. and EWING, C.M., Wild type p53 suppresses growth of prostate cancer cells containing mutant p53 alleles. Cancer Res., 51, 4716-4720 (1991).
14. KATAYOSE, D., GUDAS, J., NGUYEN, H., SRIVASTAVA, S., COWAN, K.H. and SETH, P., Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res., 1, 889-897 (1995).
15. LESSON-WOOD, L.A., HALL, S.J., SEGHAL, I., WANG, J., TTMME, T.L., YANG, G., CONNELL-CROWLEY, L., ELLEDGE, S.J., ZHANG, W.W. and HARPER, J.W., In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res., 55, 5151-5155 (1995).
16. LIU, T.J., EL-NAGGAR, A.K., MCDONNEL, T.J., STECK, K.D., WANG, M., TAYLOR, D.L. and CLAYMAN, G.L., Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res., 55, 3117-3122 (1995).
17. LIU, T.J., ZHANG, W.W., TAYLOR, D.L., ROTH, J.A., GOEPFERT, H. and CLAYMAN, G.L., Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res., 54, 3662-3667 (1994).
18. MOUL, J.W., GADDIPATI, J. and SRIVASTAVA, S., Molecular biology of prostate cancer: oncogenes and tumor suppressor genes. In: N.A. DAWSON and N.J. VOGELZANG (eds.), Current clinical oncology: prostate cancer, pp. 19-46, Wiley-Liss, New York (1994).
19. NAVONE, N.M., TROCOSO, P., PISTERS, L.L., GOODROW, T.L., PALMER, J.L., NICHOLS, W.W., VON ESCHENBACH, A.C. and CONTI, C.J., p53 protein accumulation and gene mutation in progression of human prostate cancer. J. nat. Cancer Inst., 85, 1657-1669 (1993).
20. REED, J.C., bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124, 1-6 (1994).
21. SRIVASTAVA, S., KATAYOSE, D., TONG, Y.A., CRAIG, C.R., MCLEOD, D.G., MOUL, J.W., COWAN, K.H. and SETH, P., Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. Urology, 46, 843-848 (1995).
22. STRATFORD-PERRICAUDET, L.D., MAKEH, I., PERRICAUDET, M. and BRIAND, P.J., Widespread long-term gene transfer to mouse skeletal muscle and heart. J. clin. Invest., 90, 626-630 (1992).
23. VAN MEIR, E.G., POLVERINI, P.J., CHAZIN, V.R., SU HANG, H.J., DE TRIBOLET, N. and CAVENEE, W.K., Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature (Genet.), 8, 171-176 (1994).
24. VOGELSTEIN, B. and KINZLER, K.W., p53 function and dysfunction. Cell. 70, 523-526 (1992).
25. WILLS, K.M., MANEVAL, D.C., MENZEL, P., HARRIS, M.P., SUTJIPTO, S., VAILLANCOURT, M.T., HUANG, W.M., JOHNSON, D.E., ANDERSON, S.C. and WEN, S.F., Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum. Gene. Therapy, 5, 1079-1088 (1994).
26. YANG, C., CIRIELLI, C., CAPOGROSSI, M.C. and PASSANITI, A., Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res., 55, 4210-4213 (1995).
27. YANG, G., STAPLETON, A.M.F., WHEELER, T.M., TRUONG, L.D., TIMME, T.L., SCARDINO, P.T. and THOMPSON, T.C., Clustered p53 immunostaining: a novel pattern associated with prostate cancer progression. Clin. Cancer Res., 2, 399-401 (1996).
28. ZHANG, W.W., FANG, X., MAZUR, W., FRENCH, B.A., GEORGES, R.N. and ROTH, J.A., High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Therapy, 1, 1-10 (1994).